NY-DILIGENT
17.9.2020 16:19:10 CEST | Business Wire | Press release
Diligent Corporation, a leading modern governance company used by nearly 700,000 board directors and leaders, today announced additional partnerships to enhance its Modern Leadership initiative, which provides senior leaders with the resources, insights, partnerships, and technology needed to further catalyze diversity and modernize governance in their organizations. To propel Modern Leadership forward, Diligent is partnering with an additional 11 private equity firms – 21 in total – and an additional four search firms, including Heidrick & Struggles and Egon Zehnder, joining founding partner Spencer Stuart. These partners commit to posting open board opportunities specifically for diverse candidates within the Diligent Director Network.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200917005593/en/
The initiative aims to bring transparency to director recruitment systems and open the process to diverse networks. By working directly with decision-makers instrumental to disrupting the status quo, Diligent, through the Modern Leadership initiative, is leveraging data and technology to drive diversity at the highest levels of the world’s leading organizations with an emphasis on increasing opportunities and placements for historically underrepresented groups.
“Our goal with Modern Leadership is to provide companies with access to the most diverse network of talent by creating transparency into the executive and board recruitment processes,” said Brian Stafford, CEO of Diligent. “What we’ve learned over the years is that to diversify boards it is necessary to go outside traditional professional circles. In many ways we have a networking problem, not a pipeline problem. Modern Leadership solves this by offering a new level of access and transparency.”
Launched in June, the Modern Leadership initiative has seen tremendous success, approaching 100 open board roles that will be filled by diverse candidates. As part of the initiative, Diligent’s Director Network – the world’s largest and most diverse community of board-ready talent – now boasts more than 500 individuals primed for board roles as nominated by sitting public company directors. Together, Modern Leadership and the Diligent Director Network are changing the way boards identify and recruit new talent, making the board selection process more transparent than ever.
To bolster the existing momentum surrounding Modern Leadership , today, Diligent is:
- Teaming up with an additional 11 private equity firms to open board roles for diverse director candidates. The latest private equity firms to partner with Diligent are TPG, Francisco Partners, ICV Partners, GI Partners, New Mountain Capital, The Jordan Company, The Riverside Company, Palladium Equity Partners, Argand Partners, Sumeru Equity Partners and Blue Point Capital Partners. With these additions, the Modern Leadership initiative now encompasses a total of 21 private equity firms.
- Tapping additional search firms to more widely disseminate and share searches in a way that has not previously been done. In addition to a continued partnership with Spencer Stuart, the latest firms to partner with Diligent include Egon Zehnder, Heidrick & Struggles, and SPMB.
- Collaborating with the National Association of Investment Companies and the American Investment Council members to further champion the need for board diversity within leading private equity firms.
- Partnering with 10 additional organizations that are dedicated to diversifying executives and directors, including Athena Alliance, BlackNorth, Sigma Pi Phi’s Blacks on Corporate Boards Committee, and The Toigo Foundation. Through these partnerships, Diligent is expanding its Director Network to include members and affiliates of 15 organizations focused on leadership diversity.
“TPG is pleased to join Diligent’s Modern Leadership initiative in support of their vision to build a dynamic and transparent marketplace for diverse talent,” said Ben Holzemer, Partner and Head of Human Capital at TPG Capital. “Over the past few years, we’ve been focused on increasing the gender, racial, and ethnic diversity of our own portfolio of company boards, and have since partnered with companies who have appointed more than 80 women directors. We look forward to leveraging Diligent’s platform to build on this exciting work, while sharing referrals to the many talented diverse executives we have been fortunate to be introduced to through our own extensive network.”
“At Egon Zehnder, we believe in leadership for a better world,” said Ashley Summerfield, Managing Partner of Egon Zehnder’s Board Practice. “We are convinced that involving an ever-more diverse range of talented individuals in the board rooms of major corporations will have a positive effect on the performance, culture, and stakeholders of organizations around the world. We are honored to be part of this initiative led by Diligent and its other partners.”
“To see real change in diverse representation – starting at the top – boards and organizations have to shift their paradigms, change their definitions, and their approach to D&I,” said Lyndon Taylor, Managing Partner of the Diversity & Inclusion Practice at Heidrick & Struggles. “We are excited to be part of Diligent’s Modern Leadership initiative and to help leaders build the best diverse teams possible.”
“There are tremendous opportunities to shift the narrative on board diversity and provide a way for organizations to connect with talent via the Modern Leadership initiative. We’re thrilled to be a part of this effort in support of members of the Toigo organization and our broader network who have aspiration and expertise to serve on boards,” said Nancy Sims, President of the Toigo Foundation.
The initial Modern Leadership partners consist of 10 leading private equity firms, including Insight Partners, Clearlake Capital, Vista Equity Partners, Hellman & Friedman, Hg, Genstar Capital, TA Associates, K1 Investment Management, Aurora Capital Partners, and Grain Management, to identify and create board roles for diverse director candidates. The launch also included a partnership with executive search and leadership advisory firm Spencer Stuart to promote and create opportunities.
About Diligent Corporation
Diligent Corporation is the pioneer of modern governance, empowering leaders to turn effective governance into a competitive advantage. Leveraging unparalleled insights from a team of industry innovators, as well as highly secure, integrated SaaS technologies, Diligent’s industry-leading suite of solutions changes how work gets done at the executive and board levels. Leaders rely on Diligent to drive accountability and transparency, while addressing stakeholder and shareholder priorities. Its applications also help streamline the day-to-day work of board management and committees, and support collaboration and secure information sharing. Designed for both public and private sector organizations, Diligent is helping to usher in a new era of modern governance.
The largest global network of directors and executives, Diligent is relied on by more than 19,000 organizations and nearly 700,000 leaders in more than 90 countries. With an eye towards inclusivity and accessibility, Diligent serves some of the largest public governing bodies, including more than 50% of the Fortune 1000, 70% of the FTSE 100, and 65% of the ASX.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200917005593/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
